Early Drug Launches Off To a Strong Start So Far in 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
2012 was a record year for drug approvals; now many of those drugs approved last year and this year are launching and off to a strong start in the first three months of 2013.
You may also be interested in...
Pharmaceutical Spending Fell Slightly; A First, Says IMS Institute
IMS report on U.S. medical trends highlights the trends in patient spending and shows that over one-third of spending was concentrated in the top five therapeutic classes in 2012.
Astellas/Medivation Strengthen Case For Xtandi In Advance Of Second Filing
New PSA data from the AFFFIRM trial in post-chemo patients indicate prostate cancer drug Xtandi works equally well regardless how advanced the disease, a meaningful finding for heavily pretreated patients like those in the trial. Interim rPFS data from a chemo-naïve study will be available in the second half of 2013, but a supplemental filing most certainly will wait for overall survival results.
Biogen Idec Undercuts Gilenya With $55,000 Yearly Price For Tecfidera
The company expects dimethyl fumarate’s strong efficacy and favorable safety and tolerability profile to be an advantage against other oral multiple sclerosis drugs.